ATG4 Antibody

What is ATG4B and what is its role in autophagy?

ATG4B (autophagy related 4B cysteine peptidase) is a critical component of the autophagy machinery, belonging to the peptidase C54 family. It functions as a cysteine protease that processes ATG8 family proteins (including LC3) by cleaving their C-terminal regions to expose glycine residues, enabling lipidation and subsequent incorporation into autophagosomal membranes. ATG4B displays broad specificity for ATG8 homologues but preferentially cleaves LC3 . This processing is essential for autophagosome formation and progression of the autophagy pathway. Additionally, ATG4B has a second function in deconjugating ATG8 proteins from autophagosomal membranes, which is important for recycling these proteins.

What applications are ATG4B antibodies suitable for in research?

ATG4B antibodies have been validated for multiple research applications, showing versatility in autophagy studies. According to technical specifications, these antibodies can be used for:

Researchers should note that optimal dilutions may be sample-dependent and should be determined experimentally for each system .

How do I select the appropriate ATG4B antibody for my experimental system?

Selection of an appropriate ATG4B antibody should be based on several critical factors:

• Species reactivity: Confirm that the antibody reacts with your species of interest. Available antibodies have been validated for human, mouse, and rat samples .

• Application compatibility: Ensure the antibody is validated for your specific application. Different antibodies may perform optimally in different applications such as WB, IHC, or IP.

• Molecular weight verification: ATG4B has a calculated molecular weight of approximately 44-48 kDa . Verify that the antibody detects the protein at the expected size.

• Clonality consideration: Polyclonal antibodies (like 15131-1-AP) offer broader epitope recognition, while monoclonal antibodies provide higher specificity for a single epitope.

• Validation data: Review published literature citing the antibody to assess its performance in experimental conditions similar to yours.

For genetically modified systems or specialized applications, consider antibodies that have been specifically validated in knockout/knockdown studies .

What controls should I include when using ATG4B antibodies?

Proper experimental controls are essential for reliable interpretation of results with ATG4B antibodies:

• Positive controls: Include lysates from cells known to express ATG4B, such as HeLa, HEK-293, or HepG2 cells .

• Negative controls: Consider using:

  • ATG4B knockout or knockdown samples when available

  • Primary antibody omission control

  • Isotype control (rabbit IgG for rabbit-derived antibodies)

  • Pre-absorption with immunizing peptide (if available)

• Loading controls: Include housekeeping proteins (e.g., GAPDH, β-actin) for western blotting to normalize protein loading.

• Molecular weight markers: Always include molecular weight standards to confirm the observed band corresponds to the expected size of ATG4B (44-48 kDa) .

These controls help validate antibody specificity and ensure experimental rigor in autophagy research.

How can I use ATG4B antibodies to study its interaction with other autophagy proteins?

The interaction between ATG4B and other autophagy-related proteins, particularly ATG8/LC3, can be studied using several approaches:

• Co-immunoprecipitation (Co-IP): ATG4B antibodies can be used to pull down ATG4B and its binding partners. Research has demonstrated that TAP-tagged Atg4 successfully co-immunoprecipitates with GFP-Atg8, confirming their interaction in vivo . The protocol typically involves:

  • Cell lysis under non-denaturing conditions

  • Incubation with ATG4B antibody (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate)

  • Capture with protein A/G beads

  • Washing and elution

  • Analysis of co-precipitated proteins by western blotting

• Proximity ligation assays: This technique allows visualization of protein-protein interactions in situ using paired antibodies.

• Mutation analysis: Studies have identified several LIR (LC3-interacting region) motifs in ATG4 that mediate its interaction with ATG8/LC3. Specifically, research has identified four putative LIR motifs in yeast Atg4, with pLIR2 (amino acids 102-105) and pLIR4 (amino acids 424-427) being evolutionarily conserved . Antibodies can be used to detect how mutations in these regions affect interactions.

For optimal results, perform these experiments under both basal and autophagy-inducing conditions (e.g., starvation), as some interactions are enhanced during autophagy activation .

How do post-translational modifications affect ATG4B detection by antibodies?

Post-translational modifications (PTMs) of ATG4B can significantly impact antibody recognition and detection, presenting important methodological considerations:

• Phosphorylation effects: ATG4B activity is regulated by phosphorylation, which can alter epitope accessibility. Consider these approaches:

  • Use phospho-specific antibodies when studying regulatory phosphorylation events

  • Include phosphatase inhibitors in lysis buffers to preserve phosphorylation states

  • Compare detection patterns before and after phosphatase treatment

• Redox-sensitive regulation: ATG4B contains redox-sensitive cysteine residues that affect its conformation and activity. When studying redox regulation:

  • Maintain reducing conditions during sample preparation

  • Consider including N-ethylmaleimide in lysis buffers to preserve redox states

  • Compare results under oxidizing versus reducing conditions

• Conformational changes: ATG4B undergoes conformational changes upon substrate binding that may expose or mask epitopes. When faced with inconsistent detection:

  • Try antibodies targeting different epitopes

  • Use both reducing and non-reducing conditions in western blotting

  • Consider native versus denaturing conditions for immunoprecipitation

These considerations are particularly important when studying ATG4B activity regulation or when inconsistent antibody performance is observed across different cellular conditions.

What approaches can resolve contradictory results when using different ATG4B antibodies?

When different ATG4B antibodies yield contradictory results, systematic troubleshooting is essential:

• Epitope mapping comparison: Different antibodies recognize distinct epitopes which may be differentially accessible:

  • Review the immunogens used to generate each antibody

  • Consider whether the epitope might be masked by protein interactions or conformational states

  • Test antibodies targeting different regions of ATG4B

• Validation with genetic approaches:

  • Use ATG4B knockout or knockdown samples as definitive controls

  • Complement with ATG4B overexpression systems

  • Consider using tagged ATG4B constructs that can be detected by tag-specific antibodies

• Cross-reactivity assessment:

  • Examine whether antibodies cross-react with other ATG4 family members (ATG4A, ATG4C, ATG4D)

  • Perform peptide competition assays to confirm specificity

  • Use immunoprecipitation followed by mass spectrometry to identify all proteins recognized

• Technical optimization:

  • Adjust antibody concentrations (test range: 1:500-1:3000 for WB)

  • Modify blocking conditions to reduce non-specific binding

  • Optimize antigen retrieval methods for IHC (e.g., TE buffer pH 9.0 or citrate buffer pH 6.0)

When publishing results, transparently report which antibody was used, including catalog number and lot, and include relevant validation data to support findings.

How can ATG4B antibodies be used to investigate the spatial dynamics of ATG4B during autophagy?

ATG4B exhibits dynamic localization during autophagy, and antibodies can reveal these spatial changes:

• Subcellular fractionation combined with western blotting:

  • Separate cellular compartments (cytosol, membrane, nuclear fractions)

  • Probe fractions with ATG4B antibodies (recommended dilution: 1:500-1:3000)

  • Compare distribution under basal versus autophagy-inducing conditions

  • Include markers for each subcellular compartment as controls

• Immunofluorescence microscopy:

  • Use paraformaldehyde fixation to preserve membrane structures

  • Apply ATG4B antibodies validated for immunofluorescence

  • Co-stain with markers for autophagic structures (LC3), ER, Golgi, or other organelles

  • Perform time-course experiments during autophagy induction

• Proximity-based labeling:

  • Use ATG4B antibodies to validate results from BioID or APEX2 proximity labeling experiments

  • Confirm interactions at autophagosomal membranes

Research has demonstrated that yeast Atg4 is recruited to the phagophore assembly site (PAS) during autophagy, and this recruitment is mediated by its interaction with Atg8 through specific LIR motifs . This recruitment can be visualized using fluorescently-tagged Atg4 and confirmed with antibody-based detection methods in fixed cells.

What are the optimal sample preparation methods for detecting ATG4B in different applications?

Proper sample preparation is crucial for successful ATG4B detection across different applications:

• Western blotting sample preparation:

  • Lysis buffer recommendation: RIPA buffer supplemented with protease inhibitors

  • Protein concentration: Aim for 20-50 μg total protein per lane

  • Denaturation: Heat samples at 95°C for 5 minutes in reducing Laemmli buffer

  • Gel percentage: 10-12% SDS-PAGE gels are optimal for resolving ATG4B (44-48 kDa)

  • Transfer conditions: 100V for 60-90 minutes or 30V overnight for efficient transfer

• Immunohistochemistry tissue preparation:

  • Fixation: 10% neutral buffered formalin, 24-48 hours

  • Antigen retrieval: TE buffer pH 9.0 (recommended) or citrate buffer pH 6.0 as alternative

  • Blocking: 5-10% normal serum (species different from primary antibody source)

  • Antibody dilution: 1:50-1:500, optimize based on tissue type

  • Incubation: Overnight at 4°C for primary antibody

• Immunoprecipitation optimization:

  • Cell lysis: Use gentle, non-denaturing lysis buffer (e.g., 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol)

  • Antibody amount: 0.5-4.0 μg antibody per 1.0-3.0 mg of total protein lysate

  • Pre-clearing: Use protein A/G beads to remove non-specific binding proteins

  • Controls: Include IgG control and input sample

When working with autophagy samples, consider the dynamic nature of the process—include both basal and autophagy-induced conditions (starvation, rapamycin treatment) for comprehensive analysis.

How should I troubleshoot weak or non-specific ATG4B antibody signals?

When encountering weak signals or non-specific binding with ATG4B antibodies, consider these methodical troubleshooting approaches:

• For weak or absent signals:

  • Increase antibody concentration (decrease dilution factor)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Enhance signal detection with more sensitive substrates (e.g., ECL Plus)

  • Verify sample integrity and protein extraction efficiency

  • Ensure target protein is not degraded by including protease inhibitors

  • Check if target protein is expressed in your experimental system

• For high background or non-specific bands:

  • Increase blocking time and concentration (5% BSA or milk)

  • Add 0.1-0.3% Tween-20 in wash buffers

  • Decrease antibody concentration

  • Pre-adsorb antibody with cell/tissue lysate from species of secondary antibody

  • Filter primary antibody solution (0.22 μm) to remove aggregates

  • For western blots: increase washing time and number of washes

• Application-specific troubleshooting:

  • IHC issues: Optimize antigen retrieval methods. ATG4B antibodies work well with TE buffer pH 9.0, but citrate buffer pH 6.0 is an alternative

  • WB problems: Adjust transfer conditions for proteins in the 44-48 kDa range

  • IP challenges: Pre-clear lysates thoroughly and extend antibody binding time

• Experimental design adjustments:

  • Include positive controls (HeLa, HEK-293, or HepG2 cell lysates)

  • Compare multiple antibodies targeting different epitopes

  • Validate with overexpression or knockdown/knockout systems

Remember that ATG4B detection can be affected by autophagy status; consider comparing samples under both basal and induced autophagy conditions.

What are the best approaches for quantitative analysis of ATG4B levels or activity?

Accurate quantitative analysis of ATG4B requires rigorous methodological approaches:

• Western blot quantification:

  • Use appropriate loading controls (GAPDH, β-actin, or total protein staining)

  • Ensure signal is within linear detection range (perform dilution series)

  • Capture images with a digital imaging system rather than film

  • Use software that corrects for background (ImageJ, Image Lab, etc.)

  • Calculate relative signal intensities normalized to loading controls

  • Perform at least three biological replicates for statistical analysis

• ELISA-based quantification:

  • Commercial kits are available for absolute quantification

  • Develop standard curves using recombinant ATG4B

  • Ensure samples fall within the linear range of the standard curve

  • Account for matrix effects by using similar sample compositions

• ATG4B activity assays:

  • Monitor cleavage of fluorogenic substrates based on LC3 sequences

  • Use LC3-I to LC3-II conversion as an indirect measure of ATG4B activity

  • Compare activity in the presence of ATG4B inhibitors as controls

  • Consider in vitro assays with recombinant proteins to isolate ATG4B activity

• Flow cytometry for cellular ATG4B levels:

  • Fix and permeabilize cells appropriately

  • Use fluorophore-conjugated secondary antibodies

  • Include isotype controls

  • Analyze median fluorescence intensity rather than percent positive

For all quantitative approaches, proper statistical analysis is essential. Report means with standard deviations or standard errors, and apply appropriate statistical tests based on data distribution and experimental design.

How can I validate ATG4B antibody specificity in my experimental system?

Rigorous validation of ATG4B antibody specificity is crucial for reliable research outcomes:

• Genetic validation approaches:

  • Knockout/knockdown controls: Use CRISPR/Cas9 knockout or siRNA/shRNA knockdown of ATG4B, which should result in reduced or absent signal

  • Overexpression controls: Compare signals between wild-type and ATG4B-overexpressing samples

  • Rescue experiments: Restore expression in knockout cells to confirm specificity

• Biochemical validation methods:

  • Peptide competition assay: Pre-incubate antibody with immunizing peptide, which should block specific binding

  • Multiple antibody comparison: Use antibodies targeting different ATG4B epitopes

  • Immunoprecipitation followed by mass spectrometry: Identify all proteins pulled down by the antibody

  • Size verification: Confirm detection at expected molecular weight (44-48 kDa)

• Cross-reactivity assessment:

  • Test antibody in cells overexpressing other ATG4 family members (ATG4A, ATG4C, ATG4D)

  • Examine reactivity in tissues from different species if working with non-human models

  • Check for unexpected bands that might represent splice variants or cross-reactive proteins

• Specialized validation approaches:

  • Epitope mapping: Identify the exact binding site using peptide arrays or mutagenesis

  • Application-specific validation: Validate separately for each application (WB, IP, IHC, IF)

  • Functional validation: Correlate antibody detection with functional assays of ATG4B activity

Antibodies that have been cited in peer-reviewed publications provide additional confidence in their specificity and performance .

How can ATG4B antibodies be used to study autophagy flux and regulation?

ATG4B antibodies can be powerful tools for investigating autophagy regulation when used in conjunction with other methodologies:

• Monitoring ATG4B regulation during autophagy:

  • Track ATG4B protein levels during autophagy induction using western blotting (recommended dilution: 1:500-1:3000)

  • Examine post-translational modifications that regulate ATG4B activity

  • Correlate ATG4B localization changes with autophagy progression using immunofluorescence

• ATG4B in the context of autophagy flux assessment:

  • Use ATG4B antibodies alongside LC3 antibodies to correlate ATG4B status with autophagosome formation

  • Monitor LC3-I to LC3-II conversion in the presence of lysosomal inhibitors

  • Assess how ATG4B levels/activity correlate with p62/SQSTM1 degradation

• Investigating regulatory mechanisms:

  • Use phospho-specific antibodies (if available) to study ATG4B regulation by kinases

  • Examine ATG4B-interacting proteins using co-immunoprecipitation followed by western blotting

  • Study how stress conditions alter ATG4B expression, localization, and post-translational modifications

• Manipulating ATG4B function:

  • Correlate effects of ATG4B inhibition or overexpression with autophagy markers

  • Studies have shown that excess inactive ATG4B blocks lipidation of ATG8 homologues and inhibits autophagy, making it a useful tool for autophagy research

Research has demonstrated that ATG4B preferentially cleaves LC3 among ATG8 homologues, and mutations in the ATG4B gene can strongly inhibit autophagosome formation . This direct connection to autophagosome biogenesis makes ATG4B antibodies valuable for studying the early stages of autophagy.

What insights can ATG4B antibodies provide about its role in disease pathogenesis?

ATG4B antibodies enable investigation of this protein's role in various disease contexts:

• Cancer research applications:

  • Compare ATG4B expression levels between normal and tumor tissues using IHC (dilution range: 1:50-1:500)

  • Correlate ATG4B expression with clinical parameters and patient outcomes

  • Investigate ATG4B as a potential biomarker or therapeutic target

  • ATG4B antibodies have successfully detected the protein in human pancreatic cancer tissues

• Neurodegenerative disease studies:

  • Examine ATG4B expression and localization in brain tissue samples

  • Correlate ATG4B function with autophagy impairment in disease models

  • Investigate potential post-translational modifications in pathological conditions

• Cardiovascular research:

  • ATG4B antibodies can detect the protein in mouse heart tissue

  • Study ATG4B's role in cardiac remodeling and response to stress

  • Investigate autophagy regulation in cardiomyocytes under pathological conditions

• Methodological approaches:

  • Tissue microarrays with ATG4B antibodies for high-throughput analysis across multiple disease samples

  • Laser capture microdissection combined with western blotting for region-specific analysis

  • Single-cell analysis techniques to examine heterogeneity in ATG4B expression

When interpreting disease-related findings, remember that alterations in ATG4B may be a cause, consequence, or compensatory response to pathological conditions. Correlation with functional autophagy assays and genetic manipulation studies is essential for establishing causality.

How should I design experiments to study ATG4B interactions with LIR-containing proteins?

The interaction between ATG4B and proteins containing LC3-interacting regions (LIRs) requires careful experimental design:

• Mapping interaction domains:

  • Research has identified several putative LIR motifs in ATG4, with key conserved motifs at positions 102-105 (pLIR2) and 424-427 (pLIR4)

  • Use site-directed mutagenesis to create point mutations in these motifs (typically changing key aromatic and hydrophobic residues to alanines)

  • Verify the effects of mutations on protein-protein interactions using co-immunoprecipitation

• Co-immunoprecipitation optimization:

  • Cell lysis should use gentle, non-denaturing conditions

  • Recommended antibody amount: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

  • Include appropriate controls (IgG control, input samples)

  • Consider crosslinking approaches for transient interactions

  • Compare interactions under basal and autophagy-inducing conditions

• Advanced interaction analysis methods:

  • Proximity ligation assay for visualizing interactions in situ

  • FRET/BRET approaches for real-time interaction monitoring

  • In vitro binding assays with recombinant proteins to determine binding affinities

  • Hydrogen-deuterium exchange mass spectrometry to map interaction interfaces

• Biological validation:

  • Examine the functional consequences of disrupting specific interactions

  • Correlate interaction strength with autophagy efficiency

  • Create mutants that enhance or disrupt specific interactions

Research has shown that mutations in the LIR motifs of ATG4 significantly impair its interaction with ATG8 in vivo, as demonstrated by co-immunoprecipitation experiments . These findings highlight the importance of these evolutionarily conserved motifs in mediating protein-protein interactions in the autophagy pathway.

What considerations are important when using ATG4B antibodies in high-throughput screening applications?

When employing ATG4B antibodies in high-throughput screening contexts, several methodological considerations are critical:

• Assay development and optimization:

  • Validate antibody performance in your specific assay format

  • Determine optimal antibody concentration through titration experiments

  • Establish robust positive and negative controls

  • Assess assay variability and dynamic range (Z-factor calculation)

  • Optimize signal-to-background ratio

• Platform-specific considerations:

  • Automated western blotting/capillary electrophoresis:

    • Ensure consistent protein loading and transfer

    • Validate antibody performance in automated systems (recommended dilution: 1:500-1:3000)

  • High-content imaging:

    • Optimize fixation and permeabilization conditions

    • Determine appropriate antibody concentration for imaging

    • Select suitable image analysis parameters

  • Reverse phase protein arrays (RPPA):

    • Validate antibody specificity in RPPA format

    • Ensure linear signal response across sample dilutions

• Data analysis approaches:

  • Implement appropriate normalization methods

  • Account for plate-to-plate variation

  • Apply statistical methods suitable for high-throughput data

  • Consider machine learning approaches for complex pattern recognition

• Quality control measures:

  • Include technical and biological replicates

  • Use internal reference controls on each plate

  • Implement batch correction methods

  • Consider antibody lot-to-lot variation

• Validation of hits:

  • Confirm findings with orthogonal approaches

  • Validate with multiple antibodies targeting different epitopes

  • Correlate ATG4B findings with functional autophagy assays

For drug discovery applications, remember that compounds may directly affect antibody binding or fluorophore properties, necessitating counter-screens to eliminate false positives. Additionally, ATG4B's role as a potential tool for characterizing isolation membranes makes it valuable in screens for autophagy modulators .

What are the critical storage and handling requirements for ATG4B antibodies?

Proper storage and handling of ATG4B antibodies is essential for maintaining their performance and extending their usable lifespan:

• Storage conditions:

  • Store at -20°C for long-term preservation

  • Most ATG4B antibodies are stable for one year after shipment when properly stored

  • Common storage buffer: PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

  • Aliquoting is generally unnecessary for -20°C storage

• Handling best practices:

  • Avoid repeated freeze-thaw cycles (more than 5)

  • Allow antibody to reach room temperature before opening the vial

  • Centrifuge briefly before opening to collect solution at the bottom

  • Use sterile technique when handling to prevent contamination

  • Return to -20°C promptly after use

• Working dilution preparation:

  • Prepare fresh working dilutions on the day of use

  • Dilute in recommended buffers (typically PBS with 0.1% BSA or similar)

  • For western blotting: 1:500-1:3000 dilution in blocking buffer

  • For IHC applications: 1:50-1:500 dilution in antibody diluent

• Special considerations:

  • Some ATG4B antibody preparations (20μl sizes) may contain 0.1% BSA as a stabilizer

  • Sodium azide in storage buffer is toxic; handle with appropriate precautions

  • Avoid contamination with bacteria or fungi

• Shipping and temporary storage:

  • Most antibodies can withstand ambient temperatures during shipping

  • Upon receipt, transfer immediately to recommended storage conditions

  • If temporary storage at 4°C is necessary, limit to 1-2 weeks

Following these handling recommendations will help ensure consistent antibody performance across experiments and maximize the lifespan of your ATG4B antibodies.

How should I design time-course experiments to study ATG4B dynamics during autophagy?

Time-course experiments are valuable for understanding ATG4B's dynamic role during autophagy progression:

• Experimental design considerations:

  • Time points selection: Include both early (15, 30, 60 min) and later (2, 4, 8, 24 h) time points after autophagy induction

  • Autophagy inducers: Compare different induction methods (starvation, rapamycin, Torin1)

  • Controls: Include both vehicle controls and basal conditions at each time point

  • Recovery phase: Consider including "wash-out" time points to study recovery dynamics

• Sample collection and processing:

  • Process all time points identically to avoid technical variation

  • Consider preparing separate sets of samples for different analyses (WB, microscopy, etc.)

  • For western blotting: use 20-50 μg total protein per lane

  • For microscopy: fix cells using consistent protocols across time points

• Analysis approaches:

  • ATG4B protein levels: Track by western blotting (1:500-1:3000 dilution)

  • Subcellular localization: Monitor by immunofluorescence or subcellular fractionation

  • Activity assessment: Correlate with LC3-I to LC3-II conversion

  • Interaction dynamics: Track associations with ATG8/LC3 by co-immunoprecipitation

• Data interpretation frameworks:

  • Plot parameters against time to visualize trends

  • Apply curve-fitting where appropriate

  • Consider rate calculations for process kinetics

  • Correlate ATG4B dynamics with standard autophagy markers

• Advanced considerations:

  • Use live-cell imaging with fluorescently tagged ATG4B for continuous monitoring

  • Consider pulse-chase approaches to track protein turnover

  • Employ pharmacological inhibitors at different time points to dissect pathway dependencies

  • Compare dynamics in different cell types or under various stress conditions

Research has shown that ATG4 recruitment to autophagosomal membranes is dynamic and regulated during autophagy , making time-course experiments particularly informative for understanding its functional transitions.

How do I interpret conflicting ATG4B expression patterns across different experimental systems?

When faced with inconsistent ATG4B expression patterns across experimental systems, a systematic analytical approach is essential:

Proper interpretation requires integrating multiple experimental approaches. If two ATG4B antibodies show different patterns, investigate whether they recognize different isoforms, post-translationally modified forms, or have different specificities rather than immediately dismissing one as "incorrect."

What are the current research frontiers in ATG4B biology that antibody-based studies are addressing?

Antibody-based approaches are advancing several exciting frontiers in ATG4B research:

• Regulatory mechanisms controlling ATG4B function:

  • Identification and characterization of post-translational modifications

  • Elucidation of upstream regulatory pathways

  • Investigation of ATG4B conformational changes during activation/inactivation

  • Antibodies are essential tools for tracking these modifications and states

• Non-canonical functions beyond autophagy:

  • Emerging roles in secretory pathways

  • Potential nuclear functions and transcriptional regulation

  • Involvement in inflammation and immune signaling

  • Specialized antibodies can track ATG4B in these non-autophagic contexts

• ATG4B in disease mechanisms and therapeutics:

  • Role in cancer progression and treatment resistance

  • Contributions to neurodegenerative pathologies

  • Involvement in infectious disease processes

  • Antibodies enable tissue microarray studies across disease states

• Structural and mechanistic insights:

  • Detailed mapping of protein-protein interaction domains

  • Research has identified specific LIR motifs in ATG4 (pLIR2 at positions 102-105 and pLIR4 at positions 424-427) that mediate critical interactions

  • Investigation of substrate specificity determinants

  • Conformation-specific antibodies could provide unique insights

• System-level integration of ATG4B function:

  • Coordination with other ATG4 family members (ATG4A, ATG4C, ATG4D)

  • Integration with broader stress response pathways

  • Cell type-specific regulation and function

  • Antibody panels targeting multiple autophagy components enable systems biology approaches

Current research suggests that ATG4B is not simply a constitutively active enzyme but is subject to sophisticated regulation and has diverse functions beyond its canonical role in ATG8/LC3 processing . Antibody-based studies continue to be essential for elucidating these complex aspects of ATG4B biology.

How can I integrate ATG4B antibody data with other autophagy assessment methods?

Comprehensive autophagy research requires integration of ATG4B antibody data with complementary methodologies:

• Multi-parameter autophagy assessment strategy:

  • Combine ATG4B detection (WB: 1:500-1:3000 dilution) with standard autophagy markers

  • Integrate with flux measurements (LC3-II turnover, p62 degradation)

  • Correlate with ultrastructural analysis (electron microscopy)

  • Include functional readouts (long-lived protein degradation, mitophagy assays)

• Technological integration approaches:

  • Correlative light and electron microscopy: Combine immunofluorescence of ATG4B with ultrastructural analysis

  • Multi-omics integration: Correlate ATG4B protein levels with transcriptomics and metabolomics data

  • High-content screening: Multiplex ATG4B detection with other autophagy markers

  • Live-cell imaging: Combine with endpoint immunodetection for temporal-spatial analysis

• Data integration frameworks:

  • Develop scoring systems that incorporate multiple autophagy parameters

  • Use machine learning approaches for pattern recognition across multiple datasets

  • Apply mathematical modeling to understand system-level regulation

  • Create visualization tools that display relationships between multiple autophagy components

• Experimental design for integrated analysis:

  • Include shared controls across all methodologies

  • Collect samples in parallel for different analytical approaches

  • Design time-course experiments that accommodate multiple assays

  • Consider genetic manipulations (ATG4B overexpression, knockdown) across all methodologies